Propanc Biopharma Inc (OTCMKTS: PPCB) has been moving up the charts steadily in recent days since briefly dipping below $0.015. The stock has a history of big moves running from sub pennies to highs of $0.2688 in September.
On January 2 PPCB announced a cooperation agreement has been entered into between the University of Jaén and Propanc to commence the POP1 joint drug discovery program to be co-funded by both parties. The agreement coincides with the appointment of research scientist, Mr. Aitor González, to lead the drug discovery and research activities over the next 3 to 4 years. The objective of the program is to identify and develop suitable backup compounds to Propanc’s lead product candidate, PRP. Dr. Julian Kenyon, Propanc’s Chief Scientific Officer stated:
“Identifying and developing back up compounds to our lead product candidate, PRP, is part of our long-term vision to commercialize targeted therapies which treat and prevent the spread of cancer, but without the side effects normally associated with standard treatment approaches. The world-class facilities and expert scientific researchers at Jaén and Granada Universities are dedicated to helping us achieve our vision, and we look forward to deepening our pipeline through this research collaboration.”
Propanc Biopharma Inc is a biopharmaceutical company developing new cancer treatments initially for patients suffering from pancreatic, ovarian and colorectal cancers. We have developed a formulation of anti-cancer compounds, which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body by targeting and eradicating cancer stem cells. Our products involve or employ pancreatic proenzymes, which are inactive precursors of enzymes. In the near term, we intend to target patients with limited remaining therapeutic options for the treatment of solid tumors. In future, we intend to develop our lead product candidate to treat (i) early stage cancer and (ii) pre-cancerous diseases and (iii) as a preventative measure for patients at risk of developing cancer based on genetic screening.
PPCB lead product candidate is PRP, a solution for intravenous administration of a combination of two pancreatic proenzymes trypsinogen and chymotrypsinogen. Progressing towards a First-In-Human study, PRP seeks to prevent recurrence and metastasis from solid tumors by targeting and eradicating cancer stem cells. Eighty percent of cancers are solid tumors and metastasis is the main cause of patient death from cancer. According to the World Health Organization, 8.2 million people died from cancer in 2012. A report by IMS Health states innovative therapies are driving the global oncology market to meet demand, which is expected to reach $150 billion by 2020. The Company’s initial target patient populations are pancreatic, ovarian and colorectal cancers, representing an estimated combined market segment of $14 billion in 2020, according to GBI Research.
To Find out the inside Scoop on PPCB Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
Further, the Company is working with its advisors, to explore ways to restructure and strengthen the Company’s balance sheet to ensure the Company is sufficiently resourced to progress its lead product candidate, PRP, into a first-in-human study in advanced cancer patients.
In December Propanc announced its foundation patent application has been granted by the Office of the Controller General of Patents, Design and Trademarks, India. The foundation patent, which covers the Company’s lead product candidate, PRP, pioneers the discovery of a pharmaceutical composition for treating cancer via a combination of trypsinogen and/or chymotrypsinogen pancreatic proenzymes. A report by PWC looking at prospects for growth, predicts that the Indian Pharmaceutical market will reach $50 Billion and become one of the sector’s top 10 markets in the world by 2020.
“Building a robust patent portfolio has been a top priority in driving our drug development technology forward. Adding India to the growing list of countries where we have been granted patents reflects the strength of our growing IP portfolio for PRP,” said James Nathanielsz, Propanc’s Chief Executive Officer. “Historically, patent prosecution in this region is challenging, especially in the biopharmaceutical sector, but we believe the smooth process reflects the quality of our claims and the strength of our technology. We are very excited to have this key global region under patent protection and have only two jurisdictions remaining to attain global patent protection in all countries selected for prosecution.”
We have a Monster Pick Coming. Subscribe Right Now!
Currently trading at a $4.5 million market valuation PPCB has little assets, growing debt and no revenues to date. But there is a lot to get excited about on PPCB, this is a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers. These are all multi-billion dollar markets and any advancements in any of these fields could be big considering the $3.1 total market valuation of Propanc Biopharma. Currently running up the charts on significant dollar volume investors are all over this one. We will be updating on PPCB when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with PPCB.
Sign Up now for our 100% FREE Penny Stock Newsletter
Disclosure: we hold no position in PPCB either long or short and we have not been compensated for this article.